Why Wall Street has eyes for Cures 2.0
Wall Street has high hopes for the big biomedical research package dubbed “Cures 2.0,” which Congress is poised to take up in the new year.
Stay updated with breaking news from Future Pulse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Wall Street has high hopes for the big biomedical research package dubbed “Cures 2.0,” which Congress is poised to take up in the new year.
Americans’ increased acceptance of virtual health monitoring will drive sales of health apps and wearable devices in the next few years, according to projections from Deloitte.
New research in the journal Health Affairs suggests the flood of investment could be pushing hospitals to chase profits.
The burst of interest is heightening concerns about whether there’s enough government oversight of the technology.
The Biden administration plans on Nov. 8 to lift a ban on vaccinated international travelers entering the U.S. without setting a federal standard for a digital verification system.